drugset
drugset / Trial / NCT05407779

Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

NCT05407779 ↗

Phase 1 Completed 39 enrolled Biocad
Non-randomizedSequentialOpen-labelOther

Summary

The aim of the study is to investigate the pharmacodynamics, pharmacokinetics, safety, and immunogenicity of BCD-180 after a single intravenous administration in escalating doses to healthy volunteers.

Timeline

Start
2021-01-22
Primary completion
2023-09-30
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BCD-180 Monoclonal antibody — Intravenous

Indications

No indication recorded.